Business Standard
Sunday, May 27, 2012
drived banner
drived banner
  Advanced Search
RSS
Content Guide
Follow us on  
||Companies & Industry||||||| 
 Section Home | News Now | Today's Paper | Q&A | People in the News | Industry News | Features | The Compass | Research & Analysis | Opinion | Corporate Results
Home > Companies & Industry Live Markets | Commodities
 

Cipla to export anti-Swine flu drugs to US
Press Trust of India / Mumbai Nov 11, 2009, 21:25 IST

Pharma firm Cipla today said it is looking to export Antiflu, the drug used in the treatment of influenza AH1N1 (swine flu) virus, to US markets.

"There is a shortage of this drug in the US. We have made an offer and willing to make this drug available in the US markets," Cipla Chairman and Managing Director Y K Hamied told reporters here.

cipla
BSE | NSE
Price  
cipla
Other countries also can approach us for the supply of Antiflu, he said while announcing the launch of the drug.

"We have launched Oseltamivir brand, called Antiflu, which is the only anti-flu medicine from India to be prequalified by the World Health Organisation (WHO)," Hamied said.

The company has the capacity to produce up to 2 million doses a month to meet the growing requirement of this medicine.

Currently Roche, the Swiss pharmaceuticals group which makes Tamiflu, a prescription drug, have treated around 42 million patients of H1N1 in about 80 countries worldwide.

Cipla's Antiflu would be available both in capsules and liquid. Ten capsules will cost Rs 475 and 75 ml syrup will be similarly priced.

The launch of Antiflu comes in the wake of WHO declaring the flu as pandemic, which is anticipated to strike with the seasonal peak of winter, Hamied said.

Antiflu would be sold under Schedule X category in India, like Virenza, he said.

Unlike paracetamol prescribed to control fever, Antiflu and Virenza directly targets the virus and blocks its replication, Hamied said.

Influenza, a perceivably benign condition, actually kills about 2.5-5 lakh people every year worldwide according to WHO. These are generally the elderly or those with chronic underling conditions of the lung, heart, kedney etc, he said.

The fatality pattern this year with the 2009 H1N1 virus has been unusual with the virus attacking healthy adults and children and pregnant women, Cipla's Medical Director J A Gogtay said.

Both inluenza and H1N1 are extremely contagious and Antiflu and Virenza are also recommended as preventive therapy for people with vulnerable health conditions such as asthma, COPD, HIV, heart disease or diabetes, Gogtay said.

However, medicines should be taken only with the advice of a medical practitioner, he said.

New Ipad Application :Business Standard's all new IPad App
Click here to download for free
Arrow Other Stories     
- Markets end flat
- IFC plans to invest in Malaysia's Khazanah healthcare arm
- Cong leaders must work together for winning elections: Scindia
- Hotel Leelaventure redeems outstanding bonds worth $41.6 mn
- Ex-Galleon portfolio manager testifies against Rajat Gupta
  Read Business news in 
- Journey on, We are by Your Side. Click here to know more
- 2 Lac Apartments, 1 Lac House / Plots. Click here
- Benefits Upto Rs. 2.36 Lakhs on the Fully Loaded TJet Petrol.
- The Best Seller is Also the No. 1 in Mileage. Click here
- Watch The Film Here. Click here to know more..
- Leader in Passenger Car & Automobile Tyres. Click here
- 1 billion in saving for Unilever without any tangles.
- A Brand New Server at a Price That Fits Your Budget. Click here
- Learn How One City is Running on FOOD SCRAPS.
- One Partnership Endless Possibilities. Click here to know more
- Helping doctors detect diseases earlier, saving costs & extending lives.
- 36 Lakhs can get you a pool of Luxuries. Click here
- Which is the best plan for your daughter
- Check out the TRUE COLOURS of your Stocks, Now for FREE!
- One of the leading business schools in the world.Know More
Sorry, comments to this story are closed
Latest Messages
Table for Two
  Now available at Special price
  Rs.280/- Only

  Buy Now
BS POLL
UPA 2 has completed three years. How do you rate its performance?  Read the story
  Good
  Average
  Bad
Submit
Most Popular
Read
E-Mailed
Commented
   
- EGoM to now decide on base price for spectrum auction
- Air India pilots wanted a halt to command training of IA pilots
- Rohit Viswanath: The news about soft power
- New power equation in BJP
- Traders go long on $-Re , short on Euro-Re
 
 More  
Tax Shastra
  Now available at Special price
  Rs. 360/- Only

  Buy Now
 
  Member Area Write to the Editor RSS Archives Advanced Search
  Subscribe to BS print product BS e-paper Newsletter Portfolio Tracker
  BS Products BS Hindi BS Motoring BS Books
Home | Markets & Investing | Companies & Industry | Banking & Finance | Economy & Policy | Opinion
Life & Leisure | Management & Marketing | Tech World | General News
About Us | Partner With Us | Code of Conduct | Careers | Advertise with us| Terms & Conditions | Disclaimer | Contact Us